Published in Hypertension on January 08, 2007
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension (2008) 1.72
Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension (2011) 1.24
The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol (2010) 1.23
Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension (2010) 1.18
Preeclampsia: long-term consequences for vascular health. Vasc Health Risk Manag (2015) 1.08
Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol (2011) 1.00
Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension (2013) 0.95
Renin angiotensin signaling in normal pregnancy and preeclampsia. Semin Nephrol (2011) 0.95
Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther (2008) 0.94
Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol (2012) 0.93
Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. Hypertension (2012) 0.93
Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia. Circulation (2012) 0.90
Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia. Minerva Ginecol (2012) 0.90
Elucidating immune mechanisms causing hypertension during pregnancy. Physiology (Bethesda) (2013) 0.89
Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res (2014) 0.88
Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med (2012) 0.87
Questionable role of the angiotensin II receptor subtype 1 autoantibody in the pathogenesis of preeclampsia. Hypertension (2007) 0.81
Pregnancy Complications and Later Development of Hypertension. Curr Cardiovasc Risk Rep (2013) 0.81
Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: data from the Norwegian HUNT2 study. BMC Med Genet (2014) 0.80
The role of angiogenic, anti-angiogenic and vasoactive factors in pre-eclamptic African women: early- versus late-onset pre-eclampsia. Cardiovasc J Afr (2012) 0.79
Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice. Am J Transl Res (2014) 0.79
RAS in Pregnancy and Preeclampsia and Eclampsia. Int J Hypertens (2012) 0.77
Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats. Am J Physiol Regul Integr Comp Physiol (2015) 0.76
A Dormant Microbial Component in the Development of Preeclampsia. Front Med (Lausanne) (2016) 0.76
Association of maternal AGTR1 polymorphisms and preeclampsia: a systematic review and meta-analysis. J Matern Fetal Neonatal Med (2012) 0.76
Identifying immune mechanisms mediating the hypertension during preeclampsia. Am J Physiol Regul Integr Comp Physiol (2016) 0.75
Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia. Curr Hypertens Rep (2016) 0.75
Exposure to placental ischemia impairs postpartum maternal renal and cardiac function in rats. Am J Physiol Regul Integr Comp Physiol (2017) 0.75
Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia. Hypertension (2017) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol (2003) 7.02
Living with or without cyclins and cyclin-dependent kinases. Genes Dev (2004) 6.54
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med (2008) 5.11
CDK inhibitors: cell cycle regulators and beyond. Dev Cell (2008) 5.07
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. J Nutr (2007) 4.61
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
The renal arterial resistance index and renal allograft survival. N Engl J Med (2003) 4.36
Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab (2007) 4.16
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med (2009) 4.07
Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell (2003) 3.91
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol (2008) 3.82
A new description of cellular quiescence. PLoS Biol (2006) 3.56
Pregnancy outcomes with weight gain above or below the 2009 Institute of Medicine guidelines. Obstet Gynecol (2013) 3.46
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int (2009) 3.41
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. Pediatrics (2010) 3.39
Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol (2005) 3.28
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev (2004) 3.16
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Kinase-independent function of cyclin E. Mol Cell (2007) 3.03
Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol (2008) 3.00
Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev (2007) 3.00
Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J Am Coll Cardiol (2012) 2.97
Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol (2008) 2.96
Urinary neutrophil gelatinase-associated lipocalin distinguishes pre-renal from intrinsic renal failure and predicts outcomes. Kidney Int (2011) 2.94
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev (2006) 2.89
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension (2005) 2.58
Weight loss and the renin-angiotensin-aldosterone system. Hypertension (2005) 2.58
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol (2002) 2.50
Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet (2004) 2.45
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension (2004) 2.41
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (2010) 2.38
Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell (2007) 2.38
Long-term space flight simulation reveals infradian rhythmicity in human Na(+) balance. Cell Metab (2013) 2.38
Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA (2002) 2.36
Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis (2009) 2.34
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. Science (2008) 2.29
Periadventitial fat releases a vascular relaxing factor. FASEB J (2002) 2.29
Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ Res (2007) 2.25
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Subclassification of preeclampsia. Hypertens Pregnancy (2003) 2.25
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens (2010) 2.23
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension (2007) 2.17
Retinol-binding protein 4 in human obesity. Diabetes (2006) 2.17
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation (2003) 2.15
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol (2005) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis (2013) 2.09
Acquired Brugada syndrome. Am J Cardiol (2003) 2.05
Association between adiponectin and mediators of inflammation in obese women. Diabetes (2003) 2.05
A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev (2006) 2.05
Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol (2005) 2.04
Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol (2011) 2.04
Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol (2004) 2.03
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03